A new era in obesity & diabetes care
From GLP-1 support
to sustainable metabolic health
Obesity and type 2 diabetes are global metabolic pandemics.
GLP-1 drugs like Ozempic, Wegovy, Mounjaro, though promising,
need structured support to deliver lasting impact.
Without it, over 30% of patients drop out in the first month.
Boli is a AI-native digital therapeutic that helps GLP-1 users manage side effects, improve adherence, and create lasting lifestyle change.
A new era in obesity & diabetes care
From GLP-1 support
to sustainable metabolic health
Obesity and type 2 diabetes are global metabolic pandemics.
GLP-1 drugs like Ozempic, Wegovy, Mounjaro, though promising,
need structured support to deliver lasting impact.
Without it, over 30% of patients drop out in the first month.
Boli is a AI-native digital therapeutic that helps GLP-1 users manage side effects,
improve adherence, and create lasting lifestyle change.
The most comprehensive GLP-1s app
Packed with features to support you — every step of the way.
From side effect tracking to meal guidance, it’s all here.
Tailored Day-to-Day Support
Get guidance that’s incredibly personalized, covering nutrition, mindset, cravings.
AI-Powered Meal Analysis
Just tell us what you eat - we’ll break it down and help you understand your real intake.
GLP-1-Focused Community
Join one of the most supportive communities for people with obesity or diabetes.
Adverse Events Monitoring
Track, decode and manage drug side effects with clarity. And so do your physician.
This treatment has been so tough, but also so important for me. To get through it, I needed real support and clear, practical advice to manage my side effects. Without that, I feel I would have gone through all of this for nothing.
- Amanda H., USA
of patients stop GLP-1 treatment
within the first month
(Blue Health Intelligence, 2024)
increase in long-term adherence
with digital support
(Prime Therapeutics, 2025)
of users experience
gastrointestinal side effects
(Biospace, 2025)
Already 35,000+ members strong
Connect with a growing community and share your experience.
I’ve tried a lot of apps before, but this one is just different. It actually understands what I’m going through.
Lena, 42, on GLP-1 for 6 months
The daily tips and reminders help me stay on track without feeling overwhelmed. It’s like having a gentle coach in my pocket.
Marcus, 57, started GLP-1 3 weeks ago
Finally, an app that speaks my language and really supports people like me. I don’t feel alone anymore.
Aisha, 35, lost 12 kg with GLP-1 and Boli
(beta testers from our communities)
The first autonomous Digital Therapeutics for GLP-1s
A comprehensive, tailored support system to guide you through your GLP-1 journey.
Evidence-based. Always.
Everything you’ll read, explore, or experience through our app is grounded in science and backed by the latest clinical research.
A true medical device
Boli will be fully certified medical device, built to the highest standards of safety, quality, and performance.
Data Safety — by design.
Your data is secure with us. We never use it without your consent, and we never will.
News
From us, and from the Metabolic Health world.
What Happens After You Stop GLP-1 Therapy? The Rebound Risk
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity treatment worldwide. But as millions of patients begin — and eventually discontinue — these therapies, one critical question remains: What happens next? A new meta-analysis published in
What Happens After You Stop GLP-1 Therapy? The Rebound Risk
The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity treatment worldwide. But as millions of patients begin — and eventually discontinue — these therapies, one critical question remains: What happens next? A new meta-analysis published in
Obesity R&D Is Booming. But Are We Ready for What Comes Next?
The global R&D landscape is shifting — and obesity is now at the center. According to the latest IQVIA Institute report on 2025 R&D trends, obesity has become one of the fastest-growing areas of clinical trial activity worldwide. In 2024
Orforglipron vs Oral Semaglutide: What the Future of GLP-1 Could Look Like
The GLP-1 revolution is just getting started. While most people today associate GLP-1 medications with weekly injections like Ozempic or Wegovy, the future may be easier to swallow — literally. A new clinical study from Eli Lilly, presented in 2024,